Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 2, 2026, 5:37 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Active Control Condition Clear all
Completed Phase 2 Interventional Results available

N-Acetyl Cysteine in Pathologic Skin Picking

NCT01063348
View directory record Official record
Conditions
Pathologic Skin Picking, Neurotic Excoriation, Psychogenic Excoriation, Dermatillomania
Interventions
N-Acetyl Cysteine, Placebo
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years to 64 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis

NCT07558668
View directory record Official record
Conditions
Moderate to Severe Atopic Dermatitis
Interventions
SYX-5219 Oral Capsule
Drug
Lead sponsor
Sitryx Therapeutics Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
6
States / cities
Arkansas City, Arkansas • Fremont, California • Plainfield, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Not yet recruiting Phase 4 Interventional

Semaglutide in Youth With Autism Spectrum Disorder

NCT07770152
View directory record Official record
Conditions
Autism Spectrum Disorder, Obesity
Interventions
Glucagon-like peptide-1 receptor agonist：Semaglutide, Lifestyle Management (LSM) Counseling
Drug · Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

FUVID Study: Functional Characterization of Children With Chronic Venous Thromboembolic Disease

NCT04583878
View directory record Official record
Conditions
Deep Venous Thrombosis, Pulmonary Embolism
Interventions
Blood draw (Visit 1), Blood draw (Visits 2 and 3)
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
8 Years to 21 Years
Enrollment
115 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2027
U.S. locations
14
States / cities
Little Rock, Arkansas • St. Petersburg, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Steps to Effective Problem Solving in Group Homes

NCT02855008
View directory record Official record
Conditions
Problem Behavior
Interventions
STEPS, Food for Life
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 1Phase 2 Interventional Results available

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

NCT01827137
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Galinpepimut-S, GM-CSF, Montanide, lenalidomide, bortezomib
Biological · Other · Drug
Lead sponsor
Sellas Life Sciences Group
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Targeted TDCS to Enhance Speech-Language Treatment Outcome in Persons With Chronic Post-Stroke Aphasia.

NCT04432883
View directory record Official record
Conditions
Stroke, Aphasia
Interventions
Active Comparator: Experimental: Active cathodal tDCS + language training, Sham Comparator: Placebo cathodal tDCS + Speech and language
Device · Behavioral
Lead sponsor
University of New Mexico
Other
Eligibility
25 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Physiological Mechanisms of Therapeutic Horseback Riding Intervention Effects in a Psychiatric Population of ASD Youth

NCT04606966
View directory record Official record
Conditions
Autism Spectrum Disorder, Mental Disorders
Interventions
Therapeutic Horseback Riding, Barn Activity, Hybrid
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 17 Years
Enrollment
236 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2025
U.S. locations
2
States / cities
Aurora, Colorado • Portland, Maine
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Not listed Phase 4 Interventional

Evaluating Sublingual Dexmedetomidine For Moderate To Severe Agitation In Inpatients With Schizophrenia Or Bipolar Disorder

NCT06093451
View directory record Official record
Conditions
Schizophrenia Agitation, Schizo Affective Disorder, Bipolar Disorder, Dexmedetomidine
Interventions
Dexmedetomidine, Lorazepam 2 MG/ML
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2023 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Study of Resistance Strengthening Versus Ambulation Post-Liver Transplant

NCT01216722
View directory record Official record
Conditions
Liver Transplantation, Resistance Training, Activities of Daily Living
Interventions
Resistance Strengthening Exercise Program
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 80 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Coral Gables, Florida
Source: ClinicalTrials.gov public record
Updated Oct 6, 2010 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 4 Interventional

Target Engagement and Response to Oxytocin

NCT03245437
View directory record Official record
Conditions
Schizophrenia
Interventions
Oxytocin nasal spray, Social Cognition Skills Training, Health Management, Placebo nasal spray
Drug · Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Withdrawn Phase 4 Interventional

Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Secondary Liver Metastases

NCT00510627
View directory record Official record
Conditions
Metastatic Liver Cancer, Secondary Liver Cancer, Liver Neoplasm
Interventions
Radiofrequency Ablation (RFA), Chemotherapy
Device · Drug
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Safety and Effectiveness of a Virtual Pediatric Cardiac Rehabilitation Program or Telerehabilitation in Children With Heart Disease

NCT06819059
View directory record Official record
Conditions
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation, Pediatric Cardiology, Telehealth, Telerehabilitation
Interventions
Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Natalizumab in Recurrent, Refractory or Progressive Pulmonary Metastatic Osteosarcoma

NCT03811886
View directory record Official record
Conditions
Pulmonary Metastatic Osteosarcoma (pOS)
Interventions
Natalizumab
Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
5 Years to 30 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

Adult Attention Deficit Hyperactivity Disorder (ADHD) Study With Amphetamine Sulfate

NCT03659929
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Amphetamine Sulfate, Placebo
Drug
Lead sponsor
Arbor Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
31
States / cities
Encino, California • Garden Grove, California • Newport Beach, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2024 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

Vitabreath Pilot in Chronic Obstructive Pulmonary Disease (COPD) Patients

NCT03349437
View directory record Official record
Conditions
COPD, Dyspnea
Interventions
Vitabreath Device, Pursed Lip Breathing
Device · Other
Lead sponsor
Philips Respironics
Industry
Eligibility
40 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Youngstown, Ohio • Jefferson Hills, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 7, 2019 · Synced Sep 2, 2026, 5:37 AM EDT
Terminated Phase 3 Interventional Results available

Apixaban in Patients With Sickle Cell Disease

NCT02179177
View directory record Official record
Conditions
Vaso-occlusive Crisis, Reduction in Hospitalizations, Sickle Cell Disease
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Nirmish Shah
Other
Eligibility
18 Years to 80 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

A Phase II, Prospective Study of MRI in the Reclassification of Men Considering Active Surveillance in Prostate Cancer

NCT01858688
View directory record Official record
Conditions
Prostate Cancer
Interventions
Multiparametric MRI, Prostate biopsy
Device · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 2, 2023 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional

Physiology, Imaging and Modeling of Essential Tremor

NCT03811405
View directory record Official record
Conditions
Essential Tremor, Parkinson Disease, Dystonia
Interventions
Active biphasic pulse stimulation---Home Settings, Active biphasic pulse stimulation---VIN Biphasic, Active biphasic pulse stimulation---Stimulator Off
Device
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 3 Interventional Results available

A Study to Assess the Efficacy of Fluticasone Furoate/Vilanterol (FF/VI) Inhalation Powder 100/25 mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50 mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

NCT01706328
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
FF/VI 100/25 Inhalation Powder NDPI, Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS, Placebo Inhalation Powder NDPI, Placebo Inhalation Powder ACCUHALER/DISKUS, Salbutamol as needed
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years and older
Enrollment
828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
16
States / cities
Clearwater, Florida • DeLand, Florida • Coeur d'Alene, Idaho + 13 more
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

The Medically Tailored Groceries and Mental Health Study

NCT07779707
View directory record Official record
Conditions
Depression / Major Depressive Disorder, Food Insecurity
Interventions
Medically Tailored, Home-delivered Groceries, Active Comparison Group: Monthly Grocery Gift Card
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Recruiting Not applicable Interventional

Web-based Mind-body Program to Improve Resilience Among Risky Substance Users With Persistent Upper Extremity Pain

NCT06991205
View directory record Official record
Conditions
Orthopedic Disorder, Nontraumatic Injury, Upper Extremity Pain, Risky Substance Use
Interventions
Web-TIRELESS, Web-MEUC
Behavioral · Other
Lead sponsor
Jafar Bakhshaie
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Not applicable Interventional Results available

A Study of the Effectiveness and Efficacy of the PowerSleep Device

NCT03162328
View directory record Official record
Conditions
Sleep Deprivation, Insufficient Sleep Syndrome, Healthy
Interventions
PowerSleep Stim, PowerSleep Sham
Device
Lead sponsor
Philips Respironics
Industry
Eligibility
21 Years to 50 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Lehigh Acres, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2021 · Synced Sep 2, 2026, 5:37 AM EDT
Completed Phase 2 Interventional Results available

NBI-98854 for the Treatment of Tardive Dyskinesia in Subjects With Schizophrenia or Schizoaffective Disorder

NCT01393600
View directory record Official record
Conditions
Tardive Dyskinesia
Interventions
NBI-98854, Placebo
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • National City, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Sep 2, 2026, 5:37 AM EDT